Emergent BioSolutions sells Baltimore-Camden facility to Bora Pharmaceuticals for $30m, transferring 350 employees.
Emergent BioSolutions is selling its Baltimore-Camden drug product facility to Bora Pharmaceuticals for approx. $30m, as part of a multi-year plan to streamline operations, boost profitability and reduce debt. The deal, expected to close in Q3 2024, includes the transfer of around 350 employees from Emergent to Bora. The Baltimore-Camden site provides clinical and commercial non-viral finish services.
June 20, 2024
5 Articles